Orphan drug status for mantle cell lymphoma vaccine

fda-logo.jpg

Specialty biopharmaceutical company Biovest International has just announced that the company's personalized cancer vaccine, BiovaxID®, which already has been granted orphan drug status by the FDA for follicular lymphoma, has received the same status for a second indication, mantle cell lymphoma.

Considering the paucity of effective treatments currently known for mantle cell lymphoma, this move by the FDA should be greeted with optimism.

You can read more about vaccines as they relate to cancer (including BioVaxID) in my recent blog entry, or at Biovest's website.

By Ross Bonander

SOURCE(S)

Biovest International, Inc

LymphomaInfo Social